Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun;31(12):1365-70.
doi: 10.1111/j.1365-2036.2010.04306.x. Epub 2010 Mar 20.

Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel?

R Sidhu  1 , P Wilson, A Wright, C W H Yau, F A D'Cruz, L Foye, S Morley, A J Lobo, M E McAlindon, D S Sanders
Affiliations

Faecal lactoferrin--a novel test to differentiate between the irritable and inflamed bowel?

R Sidhu et al. Aliment Pharmacol Ther. 2010 Jun.

Abstract

Background: Distinguishing between inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) can be challenging.

Aims: To investigate the utility of faecal lactoferrin as a marker of inflammation in patients with IBD, IBS and controls.

Methods: Disease activity in IBD patients was assessed using the modified Harvey-Bradshaw Activity Index. Stool samples were analysed using an ELISA assay.

Results: We recruited 137 patients with IBS, 126 with ulcerative colitis (UC) and 104 with Crohn's disease (CD), and 98 healthy volunteers. The median +/- IQ lactoferrin concentration (microg/g faecal weight) was 0 +/- 1.4 for IBS patients, 6.6 +/- 42 for UC patients, 4 +/- 12.7 for CD patients and 0.5 +/- 2 for healthy controls. Lactoferrin levels were significantly higher in IBD patients compared with IBS/healthy controls (P < 0.001). The median lactoferrin concentrations were significantly higher in active UC & CD patients compared with inactive patients (P < 0.001 and P = 0.002 respectively). The sensitivity, specificity, positive and negative predictive values of lactoferrin in distinguishing active IBD from IBS/healthy controls were 67% and 96%, 87% and 86.8% respectively.

Conclusions: Lactoferrin is useful to differentiate between IBD and IBS, and can be used as an adjunct to blood parameters to determine IBD patients who have ongoing inflammation.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

Publication types

LinkOut - more resources